Affordable Access

deepdyve-link
Publisher Website

Hepatitis D reactivation in a patient with metastatic renal cell carcinoma receiving sunitinib therapy.

Authors
  • Akar, Emre1
  • Yücel, Mehmet Haluk1
  • Şahin, Tunahan1
  • Tural, Deniz2
  • 1 Department of Internal Medicine, Bakırkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Faculty of Medicine, Bakirkoy, Istanbul, Turkey. , (Turkey)
  • 2 Department of Medical Oncology, Bakırkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Faculty of Medicine, Bakirkoy, Istanbul, Turkey. , (Turkey)
Type
Published Article
Journal
Tumori Journal
Publisher
SAGE Publications
Publication Date
Dec 01, 2019
Volume
105
Issue
6
Identifiers
DOI: 10.1177/0300891619840279
PMID: 30935288
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Cytotoxic and immunosuppressive therapies for cancer treatment may allow hepatitis reactivation. Hepatitis due to viral hepatitis reactivation is detected in 14%-25% of hepatitis B surface antigen (HBsAg)-positive cancer patients undergoing anticancer treatments. Drug toxicity may be confused with hepatitis reactivation, which may cause a delay in diagnosis. A 60-year-old man with metastatic renal cell carcinoma was treated with sunitinib. Sixteen months after sunitinib inception, liver enzymes were elevated and viral hepatitis reactivation was detected as hepatitis delta virus infection in the HBsAg-positive patient. Cancer patients should be screened for viral hepatitis prior to immunosuppressive therapy or chemotherapy.

Report this publication

Statistics

Seen <100 times